On Thursday, Shares of Pacific Biosciences of California (NASDAQ:PACB), gained 48.91% to $5.45.
Pacific Biosciences of California declared that its technology will be featured in 36 presentations at next week’s American Society of Human Genetics (ASHG) 2015 annual meeting taking place in Baltimore, Maryland.
The company will also display its new instrument, the Sequel(TM) System, which was launched yesterday. The Sequel System provides higher throughput, more scalability, a reduced footprint and lower sequencing project costs contrast to the PacBio(R) RS II System, while maintaining the existing benefits of the company’s SMRT Technology.
The company will host a workshop titled “Addressing Hidden Heritability through Long-Read Single Molecule, Real-Time (SMRT) Sequencing” on Wednesday, October 7 from 1-2:30 p.m. Eastern Time at the Sheraton Inner Harbor Hotel, Baltimore. The event will be hosted by Michael Hunkapiller and Jonas Korlach from Pacific Biosciences, and comprise talks by Richard Gibbs from Baylor College of Medicine and Richard Wilson from Washington University in St. Louis.
Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to assist scientists resolve genetically complex problems. Based on the Company’s Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to assist characterize epigenetic regulation and DNA damage.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD), inclined 0.08% to $98.27, during its last trading session.
Gilead Sciences declared that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for the investigational, once-daily single tablet regimen Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (TAF) 10 mg) for the treatment of HIV-1 infection. The data presented in the MAA support the use of the regimen among adult and adolescent treatment-naïve individuals, virologically suppressed adults who switch regimens and adults with mild-to-moderate renal impairment.
The CHMP’s recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union. If authorized, Genvoya would be Gilead’s first single tablet regimen to contain TAF.
TAF is a novel investigational nucleotide reverse transcriptase inhibitor (NRTI) that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF), in addition to improvement in surrogate laboratory markers of renal and bone safety as contrast to TDF in clinical trials in combination with other antiretroviral agents.
Gilead Sciences, Inc. (Gilead), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus comprise human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions.
Shares of DryShips Inc. (NASDAQ:DRYS), inclined 20.26% to $0.203, during its last trading session.
DryShips, declared that it has reached firm sales agreements with entities controlled by the Company’s Chairman and Chief Executive Officer, George Economou, to sell 17 vessels.
The 17 vessels, comprised of 13 Capesize and 4 Panamax bulk carriers, are being sold for an aggregate price of $377.0 million, counting their existing employment agreements and the assumption of $236.7 million of debt as of September 10, 2015, associated with some of the vessels. All of the individual transactions are predictable to close in the fourth quarter of 2015 and certain transactions remain subject to the approval of the applicable lending banks. These transactions were approved by the independent directors of the Company.
As a result of the Company’s decision to sell these vessels, the Company anticipates to recognize an impairment charge of about $373 million in its results for the third quarter of 2015.
In addition, the Company’s Board of Directors, has decided to classify all of the remaining vessels in the fleet, comprised of 20 Panamax and 2 Supramax bulk carriers, as held for sale, and as a result the Company anticipates to recognize an additional impairment charge of about $422 million in its results for the third quarter of 2015.
DryShips Inc. is a holding company. The Company is a provider of ocean transportation services for drybulk and petroleum cargoes through its ownership and operation of drybulk carrier vessels and oil tankers and offshore drilling services through the ownership and operation by its majority-owned partner, Ocean Rig UDW, of deepwater drilling units.
Finally, CSX Corporation (NYSE:CSX), ended its last trade with 0.45% gain, and closed at $27.02.
CSX Corporation and two leading mechanical unions, the International Association of Machinists and Aerospace Workers (IAM) and the International Association of Sheet Metal, Air, Rail and Transportation Workers (SMART), recently declared a landmark partnership that will enhance benefits for CSX employees and further improve productivity.
“This agreement is part of CSX’s focus on promoting a flexible workforce to meet changing business demands, and developing opportunities to retain and support our highly skilled workforce,” said Cressie Brown, vice president-labor relations, CSX.
Under the tentative agreement, which is being presented for ratification, members of the IAM and SMART unions will be able to perform a variety of assigned work beyond the traditional boundaries of craft or union affiliation. Covered employees will see raised pay through an hourly skill differential, improved ability to retain employment, benefits and connection to railroad retirement and an ability to perform additional locomotive rebuild work in-house with CSX employees. This new agreement builds on the success of a similar work-sharing structure implemented at the company’s Huntington Locomotive Shop in 2013.
CSX Corporation (CSX), together with its auxiliaries, is a transportation company. The Company provides rail-based transportation services, counting traditional rail service and the transport of intermodal containers and trailers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
